Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-14-077495
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-12-22 17:25:33
Reporting Period:
2014-12-18
Filing Date:
2014-12-22
Accepted Time:
2014-12-22 17:25:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1142596 Nuvasive Inc NUVA Surgical & Medical Instruments & Apparatus (3841) 330768598
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1289408 Keith Valentine 7475 Lusk Blvd.
San Diego CA 92121
Coo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-12-18 20,000 $18.31 106,471 No 4 M Direct
Common Stock Disposition 2014-12-18 14,107 $47.70 92,364 No 4 F Direct
Common Stock Disposition 2014-12-19 5,893 $47.78 86,471 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2014-12-18 20,000 $0.00 20,000 $18.31
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2016-01-03 No 4 M Direct
Footnotes
  1. Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive or purchase (as appropriate) shares pursuant to previously disclosed Company equity awards.
  2. Payment of exercise price and tax liability by Issuer's withholding of shares incident to the respective option exercise.
  3. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on December 12, 2013, which is intended to comply with Rule 10b5-1.
  4. Weighted average from 18 transactions with prices ranging from $47.5000 to $47.9500. Upon request by the Commission staff, the Issuer or a security holder of the Issuer, the Reporting Person will undertake to provide full information regarding the number of shares sold at each separate price.
  5. The option, representing a right to purchase a total of 81,534 shares, became exercisable as follows: 25% of the shares vested on January 3, 2007; 1/48th of the remaining shares vested monthly thereafter so that all shares were fully vested as of January 3, 2010, subject to continued employment through each vesting period.